drugset / Trial / NCT00494663

A Phase 2b Study of DIO-902 or DIO-902 Placebo in Addition to Metformin and Atorvastatin or Atorvastatin Placebo for Type 2 Diabetes

NCT00494663

Phase 2 Terminated 200 enrolled DiObex
RandomizedParallel-groupQuadruple-blindTreatment

Summary

DiObex Inc. is developing an experimental drug (DIO-902) that is made up of part of the ketoconazole molecule for the treatment of elevated blood glucose associated with type 2 diabetes mellitus. Ketoconazole (Nizoral®) is a drug available by prescription for the treatment of fungal infections however DIO-902 is an investigational drug. DIO-902 may lower blood glucose by lowering levels of a naturally occurring hormone called cortisol. Elevated cortisol may contribute to the development of type 2 diabetes. The purpose of this research study is to test the safety of DIO-902 when taken by mouth with metformin and the cholesterol-lowering drug atorvastatin to determine the type and severity of any side effects from this treatment. Other purposes of the study are to see how the treatment affects your blood glucose levels, cholesterol levels, blood pressure, and waist circumference.

Timeline

Start
2007-07
Primary completion
2008-03
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Levoketoconazole Unknown 150 mg Oral
Subject Levoketoconazole Unknown 300 mg Oral
Subject Levoketoconazole Unknown 450 mg Oral